Atea Pharmaceuticals (AVIR) Income from Continuing Operations (2019 - 2026)
Atea Pharmaceuticals' (AVIR) quarterly Income from Continuing Operations came in at 45440000.0 in Q1 2026, down 32.59% year-on-year from 67404764.54 in Q1 2025, and down 1.28% quarter-over-quarter from 44867000.0 in Q4 2025.
Atea Pharmaceuticals (AVIR) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Atea Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 45440000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 32.59% year-over-year to 45440000.0 in Q1 2026; TTM through Mar 2026 was 169517000.0, a 21.53% decrease from a year earlier, with the FY2025 full-year figure at 158349000.0, up 5.96% from the prior year.
- Income from Continuing Operations declined to 45440000.0 in Q1 2026 per AVIR's latest filing, from 44867000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 8066000.0 in Q3 2022 and bottomed at 63169000.0 in Q1 2024.
- The 5-year median for Income from Continuing Operations is 35467000.0 (2023), against an average of 36708176.47.
- Biggest YoY gain for Income from Continuing Operations was 71.39% in 2022; the steepest drop was 2136.06% in 2022.
- Year by year, Income from Continuing Operations stood at 34431000.0 in 2022, then retreated by 13.75% to 39164000.0 in 2023, then advanced by 14.35% to 33543000.0 in 2024, then plunged by 33.76% to 44867000.0 in 2025, then decreased by 1.28% to 45440000.0 in 2026.
- Per Business Quant, the three latest AVIR Income from Continuing Operations figures stand at 45440000.0 (Q1 2026), 44867000.0 (Q4 2025), and 42049000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Atea Pharmaceuticals | 376.19 Mn | 376.19 Mn | - | -45.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.44 Mn |
| Dec 31, 2025 | -44.87 Mn |
| Sep 30, 2025 | -42.05 Mn |
| Jun 30, 2025 | -37.16 Mn |
| Mar 31, 2025 | -34.27 Mn |
| Dec 31, 2024 | -33.54 Mn |
| Sep 30, 2024 | -31.15 Mn |
| Jun 30, 2024 | -40.52 Mn |
| Mar 31, 2024 | -63.17 Mn |
| Dec 31, 2023 | -39.16 Mn |
| Sep 30, 2023 | -33.14 Mn |
| Jun 30, 2023 | -28.18 Mn |
| Mar 31, 2023 | -35.47 Mn |
| Dec 31, 2022 | -34.43 Mn |
| Sep 30, 2022 | -8.07 Mn |
| Jun 30, 2022 | -31.34 Mn |
| Mar 31, 2022 | -42.08 Mn |
| Dec 31, 2021 | 117.13 Mn |
| Sep 30, 2021 | -28.19 Mn |
| Jun 30, 2021 | 1.54 Mn |